Intelligence · Clinical Development
Pipeline search results
Programs matching “bevacizumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 45 pipeline programs matching "bevacizumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
BEVACIZUMAB, ERLOTINIB
Fondazione Telethon ETS
Non-squamous Non-small Cell Lung Cancer
1 trial -
BOOG 2010-02 Stop&Go study
Teva Pharma GmbH
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1 trial -
Bevacizumab
Hoffmann-La Roche
Breast Cancer
1 trial -
Bevacizumab
Hospital Authority, Hong Kong
Proliferative Diabetic Retinopathy
1 trial -
Bevacizumab
Hoffmann-La Roche
B-cell Lymphoma
1 trial -
Bevacizumab
Samsung Bioepis NL B.V.
Lung Cancer
1 trial -
Bevacizumab
Pfizer
Renal Cell Carcinoma
1 trial -
Bevacizumab-Pfizer
Pfizer
Non-Small Cell Lung Cancer
1 trial -
FKB238 (bevacizumab)
Centus Biotherapeutics Europe Limited
Carcinoma, Non-Small-Cell Lung
1 trial -
Mirvetuximab soravtansine plus Bevacizumab
AbbVie
Ovarian Cancer
1 trial -
UC-IMM-2101
Ningbo Cancer Hospital
Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).
1 trial -
bevacizumab
Outlook Therapeutics NL B. V.
Neovascular Age-related Macular Degeneration
1 trial -
bevacizumab
Outlook Therapeutics NL B. V.
Age-related Macular Degeneration
4 trials -
bevacizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Disease Free Survival
1 trial -
serplulimab、bevacizumab
Changhai Hospital
Rectal Cancer
1 trial -
2024-HS-022
The First People's Hospital of Lianyungang
Platinum-sensitive Relapsed Ovarian Cancer
1 trial -
89Zr-Bevacizumab
Disc Medicine
NF2-related schwannomatosis
1 trial -
Ametinib combined with bevacizumab
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
Avastin® (bevacizumab)
United Therapeutics Europe Ltd
Corneal Neovascularization
1 trial -
BEVACIZUMAB
Pari Pharma GmbH
Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection.
1 trial -
BEVACIZUMAB, ATEZOLIZUMAB
Pari Pharma GmbH
liver transplanted patients with advanced hepatocellular carcinoma
1 trial -
Befotertinib combined Bevacizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
EGFR
1 trial -
Bevacizumab
The First People's Hospital of Lianyungang
Lung, Carcinoma
1 trial -
Bevacizumab
United Therapeutics Europe Ltd
Colorectal Adenocarcinoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.